Green Leaf Pharmaceutical (02186.HK): The innovative drug LY03015 (VMAT2 inhibitor/Sigma-1R agonist) has successfully completed bridge clinical trials in the United States.

Zhitong Finance APP reported that Green Leaf Pharmaceutical (02186.HK) announced that its self-developed new molecular entity LY03015 has successfully completed bridging clinical trials in the United States, supporting its upcoming efficacy clinical trials in the U.S. The trial also found that the Caucasian population has better safety tolerance compared to the Chinese population.